ICARES Business Summary

ICARES Medicus, Inc. (6612.TWO) operates a vertically integrated business model in the ophthalmic medical device sector, generating revenue through three primary streams: royalty income from high-end medical surface treatment licensing, technical service fees for medical coatings and foundry services, and direct sales of proprietary intraocular lenses (IOLs) and delivery systems. The company holds a dominant global position in the surface treatment niche, with its coating technology utilized in approximately 50% of all cataract surgery injectors worldwide. Following its 2024 acquisition of U.S.-based MBI, ICARES has transitioned from a technology provider to a full-scale manufacturer, employing a dual-brand strategy with its Asqelio and PreciSAL lines to capture market share in the U.S., China, and Europe. It competes directly with global ophthalmic giants such as Alcon, Johnson & Johnson Vision, Bausch + Lomb, and Hoya Surgical Optics, positioning itself as a high-growth specialist leveraging superior lubrication technology to enhance surgical safety and patient outcomes. The company was founded in 2011 by an entrepreneurial management team originating from AST Products, Inc. (Massachusetts, U.S.A.), bringing over 70 years of combined industrial expertise in medical coatings. The current leadership team is headed by Chairman Ih-Houng Loh and CEO Jeff Chen, with William Lee serving as President and Group General Manager. Under this leadership, ICARES has expanded its manufacturing footprint with high-standard cleanrooms in Hsinchu, Taiwan, and a major subsidiary, MAXUS Medical, in Shanghai to drive localized growth in the Chinese market. The board's strategic focus remains on vertical integration and global distribution, supported by a stable institutional shareholder base including State Street Global Advisors and long-term strategic partners from the biomedical science sector.